Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Bullboard Posts
Comment by rbc123on Oct 19, 2010 12:05pm
295 Views
Post# 17582199

RE: RE: RE: News ... - extract from Annual Report

RE: RE: RE: News ... - extract from Annual Report

12. Shareholders’ Equity  SERIES II PREFERRED SHARES

On November 3, 2004 the Company issued 12,000,000 shares of Series II convertible preferred stock for gross consideration of

$12,000,000. The Series II Preferred Shares are convertible at the option of the holder into Common Shares for five years plus

one day at a conversion ratio which is obtained by dividing the fully-accreted value by the applicable conversion price as follows:

25% at $1.45; 50% at $2.50; and 25% at $3.75. The fully accreted value is calculated as the aggregate subscription price of the

preferred shares plus 6% per annum until the earlier of conversion or five years from the date of issuance. Issue costs for this

private placement totaling $268,284 were netted against the share capital of the Series II Preferred Shares

On June 4, 2007, the holder converted 3,000,000 shares or 25% of their Series II convertible preferred stock at its accreted

value for conversion purposes of $3,463,068 to Common Shares at a conversion price of $1.45. As a result, 2,388,323 Common

Shares were issued.

After the initial five-year plus one-day term, any Series II Preferred Shares outstanding are convertible, at the option of the

holder, into Common Shares at the fully accreted value divided by the average market price of the Common Shares less the

greater of 5% or the maximum discount permitted by the TSX [subject to the issuance of a maximum of 6,521,677 [2008

– 6,521,677] Common Shares in the aggregate on conversion of all Series II Preferred Shares].

If the trading price of the Common Shares exceeds $13.50 for 60 consecutive days, the Company may require the holders to

convert the Preferred Shares into Common Shares at the conversion ratio applicable on the date of conversion.

The Preferred Shares have voting rights on the basis of the number of Common Shares that the holder would have if the Preferred

Shares were converted into Common Shares on the date of the applicable shareholders’ meeting
Bullboard Posts